
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc has demonstrated a strong potential for growth due to its investigational drug assets targeting Alzheimer's disease, including promising results from preclinical studies of IGC-AD1. The company’s current valuation is considered attractive, supported by an upward adjustment to its 12-month price target, indicating significant upside potential based on net present value analysis. Furthermore, the anticipation of positive data and progress in ongoing research is likely to act as a catalyst for future stock performance.
Bears say
IGC Pharma Inc. reported a net loss of $1.6 million, equating to an earnings per share (EPS) of $(0.02), which aligns with previous estimates but indicates ongoing financial challenges. The company faces significant risks, including balance sheet and liquidity issues, the potential failure of its investigational drug candidates in demonstrating safety and efficacy, and hurdles in obtaining regulatory approvals. Additionally, the competitive landscape and shifting investor sentiment towards biotech stocks further exacerbate uncertainties surrounding IGC Pharma's future performance and market position.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares